Cure8 news brief
The findings suggest blood DNA methylation changes may mark UC long before symptoms start; that could eventually enable earlier risk identification or research into preventing progression to symptomatic disease.
Researchers studying IBD biomarkers and disease mechanisms, clinicians interested in early-detection approaches for UC, and patients and advocates following advances in IBD prediction and prevention research.
Researchers used a nationwide prospective cohort with baseline whole-blood DNA methylation measured years before diagnosis.
Epigenome-wide analysis found 16 methylation changes that preceded ulcerative colitis diagnosis and yielded a prediction model with an AUC of 0.85 for future UC; models did not predict irritable bowel syndrome or rheumatoid arthritis, suggesting disease specificity.
The study detected fewer and weaker preclinical signals for Crohn’s disease, likely reflecting smaller case numbers for CD in this cohort. One methylation change previously reported in other studies was observed up to a median of 4 years before Crohn’s diagnosis.
Next steps include replication in other cohorts and investigation of whether these methylation changes are causal, reflect early immune changes, or could be combined with other markers for screening or prevention trials.
This is a single cohort study reported as a research letter in Gastroenterology. Results are promising but require replication in independent cohorts and deeper study before clinical use. The study had relatively small numbers for Crohn’s disease, which limits conclusions for CD.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This research suggests genetic risk scores could help identify people with IBD who are more likely to have severe disease, which might eventually inform earlier monitoring or treatment decisions. It’s a step toward more...
A genetic marker (HLA-DRB1*01:03) was linked to more severe IBD outcomes—higher rates of colectomy/colonic surgery, more perianal disease, earlier use and higher failure of advanced therapies—which could help explain...
This paper explores whether polygenic risk scores (PRS) predict key long-term outcomes after IBD diagnosis — notably intestinal surgery — which could be relevant for risk stratification research and future clinical tools...
